Tuesday, September 08, 2026 | 05:11 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 2 - Novartis

Novartis to cut up to 8,000 jobs globally to save $1 bn by 2024

As part of the organisational overhaul unveiled in April, Novartis said that the cost cuts would be mainly from removing overlapping structures

Novartis to cut up to 8,000 jobs globally to save $1 bn by 2024
Updated On : 28 Jun 2022 | 11:20 PM IST

Cash-flush Novartis launches new share buyback of up to $15 bn

The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month

Cash-flush Novartis launches new share buyback of up to $15 bn
Updated On : 16 Dec 2021 | 2:41 PM IST

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale
Updated On : 05 Nov 2021 | 12:37 AM IST

Novartis Q1 sales, profit miss analyst expectations amid Covid-19 impact

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%

Novartis Q1 sales, profit miss analyst expectations amid Covid-19 impact
Updated On : 27 Apr 2021 | 3:11 PM IST

Novartis, Molecular Partner team up on coronavirus candidates treatment

Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat Covid-19 patients, the two companies said

Novartis, Molecular Partner team up on coronavirus candidates treatment
Updated On : 28 Oct 2020 | 12:48 PM IST

Novartis lifts 2020 forecast as drugmakers see hospitals coping with Covid

ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

Novartis lifts 2020 forecast as drugmakers see hospitals coping with Covid
Updated On : 27 Oct 2020 | 9:00 PM IST
Top headlines: CBI, ED to charge GVK Group, Biden promises on H1-B & more
Updated On : 02 Jul 2020 | 5:16 PM IST

Novartis pays $729 mn to settle US charges that it paid doctors kickbacks

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs

Novartis pays $729 mn to settle US charges that it paid doctors kickbacks
Updated On : 02 Jul 2020 | 1:17 PM IST

Coronavirus vaccine not coming for at least 2 years: Novartis global CEO

A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts

Coronavirus vaccine not coming for at least 2 years: Novartis global CEO
Updated On : 16 May 2020 | 3:54 AM IST

Novartis confirms 2020 outlook; sales, profit up amid Covid-19 outbreak

Core net income rises to $3.55 billion from $2.8 billion in 2019, against the average analyst forecast in a Refinitiv poll of $3.17 billion

Novartis confirms 2020 outlook; sales, profit up amid Covid-19 outbreak
Updated On : 28 Apr 2020 | 8:03 PM IST

Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma

Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.

Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma
Updated On : 09 Apr 2020 | 7:26 AM IST

Novartis CEO says Malaria drug biggest hope against coronavirus: Newspaper

Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis.

Novartis CEO says Malaria drug biggest hope against coronavirus: Newspaper
Updated On : 29 Mar 2020 | 2:28 PM IST

Novartis, Merck, Allergan raise US prices, 445 drugs to cost more in 2020

That is above the average of 404 drug price increases in the first three days of January over the past five years

Novartis, Merck, Allergan raise US prices, 445 drugs to cost more in 2020
Updated On : 04 Jan 2020 | 8:09 PM IST

Switzerland is country partner for BioAsia event on February 17-19

BioAsia is an annual event in which stakeholders in the lifesciences sector discuss new innovations and explore possibility of business collaborations in the sector

Switzerland is country partner for BioAsia event on February 17-19
Updated On : 10 Dec 2019 | 6:48 PM IST

Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors

Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn
Updated On : 03 Dec 2019 | 9:02 PM IST

Novartis's $90 million Swiss factory to help solve cell therapy bottleneck

Basel-based Novartis sees cell and gene therapies eventually contributing about 15% of its revenue

Novartis's $90 million Swiss factory to help solve cell therapy bottleneck
Updated On : 28 Nov 2019 | 6:12 PM IST

Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker

Novartis shares were seen up 0.2%, premarket indicators showed.

Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker
Updated On : 26 Nov 2019 | 12:08 AM IST

Novartis buys Aspen's Japanese generic unit for up to 400 million euros

Aspen Pharmacare has abandoned its dividend this year and is selling assets to pay down debt after levels moved close to breaching debt covenants

Novartis buys Aspen's Japanese generic unit for up to 400 million euros
Updated On : 11 Nov 2019 | 8:06 PM IST

Price of key diabetes drug may crash as Novartis risks losing patent

A look at the top 10 brands of Novartis in India shows that mature brands like Voveran and Calcium Sandoz are clocking low single-digit growth

Price of key diabetes drug may crash as Novartis risks losing patent
Updated On : 09 Oct 2019 | 12:53 PM IST

Here's why Novartis CEO thinks FDA process could have been handled better

Novartis has said that it learned of the data manipulation on March 14 and alerted the US Food and Drug Administration

Here's why Novartis CEO thinks FDA process could have been handled better
Updated On : 18 Aug 2019 | 12:29 AM IST